-
公开(公告)号：US20240174759A1
公开(公告)日：2024-05-30
申请号：US18549346
申请日：2022-03-09
Applicant: GENMAB A/S , BIONTECH SE
Inventor： Yali FU , Homer ADAMS , Gaurav BAJAJ
CPC classification number: C07K16/2878 , A61K9/0019 , A61P35/00 , A61K2039/505 , A61K2039/54 , A61K2039/545 , C07K2317/31 , C07K2317/524 , C07K2317/526 , C07K2317/565
Abstract: The present disclosure relates generally to the field of multispecific binding agents for use in therapy, in particular for use in treating cancer, wherein the binding agents bind to human CD40 and to human CD137.
-
公开(公告)号：US20240132620A1
公开(公告)日：2024-04-25
申请号：US18235550
申请日：2023-08-17
Applicant: GENMAB A/S
Inventor： Michel DE WEERS , Yvo GRAUS , Judith OPRINS , Paul PARREN , Jan VAN DE WINKEL , Martine VAN VUGT
IPC: C07K16/40 , A61K39/395 , A61K49/00 , C07K14/705 , C07K16/28 , C12N5/10 , C12N15/63 , G01N33/566
CPC classification number: C07K16/40 , A61K39/3955 , A61K49/0004 , C07K14/70596 , C07K16/2896 , C12N5/10 , C12N15/63 , G01N33/566 , A61K2039/505 , C07K2317/34
Abstract: Isolated human monoclonal antibodies which bind to human CD38, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
-
113.发明授权公开(公告)号：US11932693B2
公开(公告)日：2024-03-19
申请号：US18315686
申请日：2023-05-11
Applicant: BioNTech SE , Genmab A/S
Inventor： Ugur Sahin , Sina Fellermeier-Kopf , Friederike Gieseke , Karsten Beckmann , Claudia Paulmann , Alexander Muik , Ivan Kuzmanov , Esther Cornelia Wilhelmina Breij , Patricia Garrido Castro , Jordan Blum , Lars Guelen , Joost Neijssen , Bart-Jan De Kreuk , Richard Hibbert , Janine Schuurman , Aran Frank Labrijn
IPC: C07K16/28
CPC classification number: C07K16/2818 , C07K2317/24 , C07K2317/92
Abstract: The present disclosure relates to antibodies having the ability to bind to the immune checkpoint protein programmed death-1 (PD-1), such as human PD-1, or nucleic acids encoding such antibodies, wherein the antibodies comprise modifications in the Fc region eliminating or reducing a Fc-mediated effector function of the antibodies. The present disclosure also relates to compositions or kits comprising said antibodies or nucleic acids, as well as to the use of these antibodies or nucleic acids or compositions in the field of medicine, preferably in the field of immunotherapy, e.g., for the treatment of cancers. The present invention further relates to methods for inducing an immune response in a subject comprising providing to the subject an antibody of the present disclosure or one or more nucleic acids encoding such an antibody, or a composition comprising said antibody or nucleic acids.
-
114.发明公开公开(公告)号：US20230365693A1
公开(公告)日：2023-11-16
申请号：US18315686
申请日：2023-05-11
Applicant: BioNTech SE , Genmab A/S
Inventor： Ugur SAHIN , Sina FELLERMEIER-KOPF , Friederike GIESEKE , Karsten BECKMANN , Claudia PAULMANN , Alexander MUIK , Ivan KUZMANOV , Esther Cornelia Wilhelmina BREIJ , Patricia GARRIDO CASTRO , Jordan BLUM , Lars GUELEN , Joost NEIJSSEN , Bart-Jan DE KREUK , Richard HIBBERT , Janine SCHUURMAN , Aran Frank LABRIJN
IPC: C07K16/28
CPC classification number: C07K16/2818 , C07K2317/24 , C07K2317/92
Abstract: The present disclosure relates to antibodies having the ability to bind to the immune checkpoint protein programmed death-1 (PD-1), such as human PD-1, or nucleic acids encoding such antibodies, wherein the antibodies comprise modifications in the Fc region eliminating or reducing a Fc-mediated effector function of the antibodies. The present disclosure also relates to compositions or kits comprising said antibodies or nucleic acids, as well as to the use of these antibodies or nucleic acids or compositions in the field of medicine, preferably in the field of immunotherapy, e.g., for the treatment of cancers. The present invention further relates to methods for inducing an immune response in a subject comprising providing to the subject an antibody of the present disclosure or one or more nucleic acids encoding such an antibody, or a composition comprising said antibody or nucleic acids.
-
公开(公告)号：US11814437B2
公开(公告)日：2023-11-14
申请号：US17938523
申请日：2022-10-06
Applicant: GENMAB A/S
Inventor： David Satijn , Patrick Engelberts , Kristel Kemper , Esther C. W. Breij , Simone Oostindie , Farshid Alemdehy
CPC classification number: C07K16/2878 , A61P35/00 , C07K16/2809 , C12N15/63 , C07K2317/31 , C07K2317/526 , C07K2317/565
Abstract: The invention relates to multispecific antibodies binding to CD3 and CD30. The invention further provides pharmaceutical compositions comprising antibodies of the invention, nucleic acids encoding the antibodies, host cells that produce the antibodies, methods of producing the antibodies and uses of the antibodies, in particular for cancer therapy.
-
Patent Agency Ranking
116.发明公开公开(公告)号：US20230357440A1
公开(公告)日：2023-11-09
申请号：US18025205
申请日：2021-09-10
Applicant: GENMAB A/S
Inventor： Brian ELLIOTT , Tahamtan AHMADI , Christopher W.L. CHIU , Esther C.W. BREIJ
CPC classification number: C07K16/468 , A61P35/00 , C07K2317/565 , C07K2317/31 , C07K2317/24 , C07K2317/52
Abstract: Provided are methods of clinical treatment of follicular lymphoma (for example, relapsed and/or refractory follicular lymphoma) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimens of rituximab and bendamustine.
-
117.发明公开公开(公告)号：US20230355753A1
公开(公告)日：2023-11-09
申请号：US18025206
申请日：2021-09-10
Applicant: GENMAB A/S
Inventor： Brian ELLIOTT , Tahamtan AHMADI
IPC: A61K39/395 , A61P35/00 , A61K31/573 , A61K31/7068 , A61K31/282
CPC classification number: A61K39/3955 , A61P35/00 , A61K31/573 , A61K31/7068 , A61K31/282 , A61K2039/545
Abstract: Provided are methods of clinical treatment of diffuse large B-cell lymphoma (DLBCL) (e.g., relapsed and/or refractory DLBCL eligible for autologous stem cell transplant) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimen of R-DHAX/C (rituximab, dexamethasone, cytarabine, and oxaliplatin/carboplatin).
-
118.发明公开公开(公告)号：US20230303693A1
公开(公告)日：2023-09-28
申请号：US18160391
申请日：2023-01-27
Applicant: GENMAB A/S
Inventor： Christopher W. L. CHIU , Mariana Cota STIRNER , Minh H. DINH , IIiana Edith SZAFER-GLUSMAN
IPC: C07K16/28 , A61P35/00 , A61K47/68 , A61K39/395 , A61K31/675 , A61K31/704 , A61K31/573
CPC classification number: C07K16/2809 , A61P35/00 , A61K47/6811 , A61K47/6867 , A61K39/3955 , A61K31/675 , A61K31/704 , A61K31/573 , C07K16/2887 , A61K2039/507
Abstract: Provided are methods of clinical treatment of diffuse large B-cell lymphoma (DLBCL) (e.g., previously untreated DLBCL) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with Pola-R-CHP (polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone).
-
119.发明公开公开(公告)号：US20230263902A1
公开(公告)日：2023-08-24
申请号：US18010783
申请日：2021-06-29
Applicant: Genmab A/S
Inventor： Reshma A. RANGWALA
CPC classification number: A61K47/6803 , A61K47/6849 , A61P35/00 , A61K9/0019
Abstract: The invention provides methods and compositions for treating cancer, such as advanced cervical cancer, in a subject, such as by the administration of antibody-drug conjugates that bind to tissue factor (TF). The invention also provides articles of manufacture and compositions comprising said antibody drug-conjugates that bind to TF for use in treating cancer (e.g., advanced cervical cancer).
-
公开(公告)号：US20230227495A1
公开(公告)日：2023-07-20
申请号：US17939736
申请日：2022-09-07
Applicant: Genmab A/S
Inventor： Michael GRAMER , Amitava Kundu , Ewald T. J. Van Den Bremer , Muriel Van Kampen , Patrick Priem , Aran Frank Labrijn , Joyce I. Meesters , Joost J. Neijssen , Janine Schuurman , Paul Parren , Patrick Van Berkel , Werner L. Vos , Amout F. Gerritsen
CPC classification number: C07K1/1133 , C07K16/2863 , C07K16/2887 , C07K16/468 , C07K2317/24 , C07K2317/31 , C07K2317/41 , C07K2317/524 , C07K2317/526 , C07K2317/53 , C07K2317/55 , C07K2317/732 , C07K2317/734 , C07K2317/90
Abstract: The present invention relates to an in vitro method for production of heterodimeric proteins.
-
-
-
-
-
-
-
-
-
Search Results
274
records
(took 0.144 seconds)
